TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06471855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Conventional and Technology-based Rehabilitation
Description: Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy), the Walker ViewTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary Conventional Rehabilitation
Description: Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
Study: NCT05793489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions.
Study: NCT05847114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stres ball
Description: Stress ball compression for 15 minutes during surgery
Study: NCT05667623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406 Ointment
Description: Twice-daily administration for 4 weeks/24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0% OPA-15406 Vehicle
Description: Twice-daily administration for 4 weeks/24 weeks.
Study: NCT05020314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight Clinic
Description: Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
Study: NCT05411939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making Tool
Description: The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.

Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Short video that describes knee osteoarthritis and possible treatment options.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Short video that describes knee osteoarthritis and possible treatment options.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care counseling for a patient presenting with knee osteoarthritis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care counseling for a patient presenting with knee osteoarthritis.
Study: NCT06315127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human donor milk
Description: The intervention will involve providing donor milk as required as a supplement to parent milk and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. All donor milk will be aliquoted into individualized syringes in the Rogers Hixon Ontario Human Milk Bank which is located in Sinai Health. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad. As this study follows a pragmatic approach, the clinical team will assess the need for supplementation based on the mother-infant dyad's condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula
Description: The intervention will involve providing formula as required as a supplement to parent milk and as a standard of care, and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. The formula will be supplied from the hospital's inventory in accordance with the standard procedure followed by the well-baby unit to supplement infants. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad.
Study: NCT06529861

Intervention type: DIAGNOSTIC_TEST
Intervention: [15O]H2O-PET Imaging
Description: This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: [15O]H2O-PET Imaging
Description: This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
Study: NCT04794075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Education and Nursing Support Program for Supportive Care
Description: In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program.
Study: NCT05809362

Intervention type: DEVICE
Intervention: WHOOP 4.0 Strap
Description: Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.

Intervention type: DEVICE
Intervention: WHOOP 4.0 Strap
Description: Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.

Intervention type: DEVICE
Intervention: BioTel ePatch
Description: Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.

Intervention type: DEVICE
Intervention: BioTel ePatch
Description: Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
Study: NCT04667104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monohydrate
Description: ETV monohydrate film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha2a
Description: PegIFN-alpha2a injection will be administered subcutaneously once weekly.
Study: NCT06183333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heidelberg Emotion Regulation Training
Description: The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
Study: NCT06279507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride 2 mL prepared in plastic syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: 10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: 10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
Study: NCT04887987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training + active PBMT
Description: Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pilates training + sham PBMT
Description: Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training + active PBMT
Description: Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Multicomponent training + sham PBMT
Description: Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
Study: NCT06443099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different methods used after intramuscular injection
Description: Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different methods used after intramuscular injection
Description: Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
Study: NCT05100446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin - high dose dual therapy
Description: Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pylera
Description: Eradication with Pylera, for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg, twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg, twice a day.
Study: NCT06477185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
Study: NCT04530864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
Study: NCT05114876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent delirium-risk prevention bundle
Description: This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses.
Study: NCT06390709

Intervention type: OTHER
Intervention: Lab Collection Only
Description: 2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
Study: NCT03862924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized Research Electronic Cigarette
Description: Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
Study: NCT06091969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active multi-ingredient supplement (Fertility Enhancer, FE)
Description: Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
Study: NCT05387564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCT Documentation and Disclosure Toolkit (SCT-DD)
Description: A toolkit of implementation strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCT Documentation and Disclosure Toolkit (SCT-DD)
Description: A toolkit of implementation strategies
Study: NCT04620681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Description: Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Description: Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Description: Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Description: Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care cytarabine-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care cytarabine-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care cytarabine-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care cytarabine-based chemotherapy
Study: NCT05453565

Intervention type: OTHER
Intervention: Vasopressors
Description: A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets

Intervention type: OTHER
Intervention: Fluids
Description: A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
Study: NCT04944966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maytenus Senegalensis
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maytenus Senegalensis
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maytenus Senegalensis
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg
Study: NCT06091969

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo (Placebo; PLA)
Description: Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
Study: NCT05991869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Point-of-care decision support intervention
Description: PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly.
Study: NCT05548387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once per period.
Study: NCT04975295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04784832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervicomedullar stimulation
Description: Electric stimulation of the muscle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervicomedullar stimulation
Description: Electric stimulation of the muscle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervicomedullar stimulation
Description: Electric stimulation of the muscle
Study: NCT06542614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3906 capsules
Description: To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of TQH3906 capsules
Description: Placebo without drug substance.
Study: NCT05419596

Intervention type: PROCEDURE
Intervention: Urologic Surgery
Description: Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).